ArticleFrontiers in neurology2022

OzEAN Study to Collect Real-World Evidence of Persistent Use, Effectiveness, and Safety of Ozanimod Over 5 Years in Patients With Relapsing-Remitting Multiple Sclerosis in Germany.

Tjalf Ziemssen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.